A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Phase 2 Completed 224 enrolled Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Main military clinical hospital named after academician N. N. Burdenko · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

The aim of the present study is at the first stage: a comparative assessment of the safety of the two methods of vaccine administration, at the second - an assessment of the safety and state of post-vaccination immunity at different times after vaccination

Timeline

Start: 2019-10-18
Primary completion: 2020-06-30
Completion: 2020-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GamFluVac	Vaccine	2.5e+11 unknown	Intranasal

Indications

No indication recorded.